Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/61353
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK |
Author: | Karnon, J. Holmes, M. Williams, R. Bakhai, A. Brennan, A. |
Citation: | International Journal of Cardiology, 2010; 140(3):315-322 |
Publisher: | Elsevier Sci Ireland Ltd |
Issue Date: | 2010 |
ISSN: | 0167-5273 1874-1754 |
Statement of Responsibility: | Jonathan Karnon, Mike W. Holmes, Robert Williams, Ameet Bakhai, Alan Brennan |
Abstract: | Design: Cost utility analysis using a cohort Markov model, incorporating clinical data from two pivotal clinical trials (the COMMIT/CCS-2 and CLARITY-TIMI 28 trials) and data from UK and non-UK observational studies. Setting: Health economic evaluation carried out from the perspective of the UK NHS. Patients: A representative cohort of 1000 UK patients aged 60 years, diagnosed with STEMI. Interventions: 75 mg/day clopidogrel, with and without a 300 mg loading dose, in addition to standard therapy (including aspirin, 75–325 mg/day) for 1 month, and for 1 year, followed by standard therapy alone for their remaining lifetime, or standard therapy alone (including aspirin, 75–325 mg/day) for their remaining lifetime. Main outcome measures: Incremental cost per quality-adjusted life-year (QALY) gained (ICER). Results: For the 1-month treatment option both the COMMIT/CCS-2 and CLARITY-TIMI 28 trials have ICERs below £2500. For the 1-year treatment option both trials have ICERs below £4000. Extensive univariate and probabilistic sensitivity analyses showed these results to be robust. Conclusions: In combination with previous economic analyses of clopidogrel in NSTEMI patients, this paper demonstrates that clopidogrel appears to offer a cost-effective treatment option for all ACS patients. |
Keywords: | ST elevation acute myocardial infarction (STEMI) Aspirin, Clopidogrel Cost effectiveness Markov model QALYs |
Rights: | Copyright © 2008 Elsevier Ireland Ltd. All rights reserved. |
DOI: | 10.1016/j.ijcard.2008.11.105 |
Published version: | http://dx.doi.org/10.1016/j.ijcard.2008.11.105 |
Appears in Collections: | Aurora harvest 5 Public Health publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.